Aristotle University Of Thessaloniki (AUTH)
Σχεδιασμός και φαρμακοχημική μελέτη νέων ενώσεων με πιθανή δράση σε νευροεκφυλιστικές διαταραχές
Abstract
dc:descriptionAlzheimer’s Disease (AD) is one of the most common neurodegenerative disorders, responsible for about 70% of dementia cases worldwide. According to the World Alzheimer Report, about 45 million people were affected by AD in 2015 and this number is projected to increase to 75 million by 2030. AD is characterized by short- and long-term memory loss and cognitive dysfunction. Ηaving in mind the increase of life expectancy, the socio-economic impact of this disease is expected to rise significantly. Current AD therapies either relieve symptoms temporarily by inhibiting acetylcholinesterase (AchE) and thus increasing the activity of acetylcholine or regulating the activation of NMDA receptors. Ineffective treatment of AD can be attributed to the multi-factorial character of the disease, as various biochemical pathways are disrupted. The histopathological hallmark lesions are extracellular deposits of β-amyloid peptides and intracellular neurofibrillary tangles (NFTs), of hyperphosphorylated tau-protein. In addition to senile plaques and NFTs, oxidative stress has been found to play a key role in the development of AD. Large amounts of oxygen are consumed in the brain, therefore high concentrations of Reactive Oxygen Species (ROS) are produced there. Due to low antioxidant protection of the Central Nervous System (CNS), oxidative stress is easily established, resulting in lipid peroxidation, protein oxidative damage, leading to cellular death and neurodegeneration. Moreover, oxidative stress induces β-amyloid peptide aggregation and NFT formation and leads to the production of Advanced Glycation End-products (AGEs), that are characterized by neurotoxicity. Inflammation is another key factor contributing to AD development. Microglia activation leads to immune-response and subsequently to the production of inflammation mediators, such as cytokines and prostaglandins. Inflammatory enzymes such as lipoxygenases (LOX) and cyclooxygenases (COX) are overexpressed during AD, resulting in general inflammatory reactions causing apoptosis and neurodegeneration. As far as neurotransmitters are concerned, acetylcholine is found in very low concentrations, while NMDA receptors are overactive, leading to excitotoxicity. Moreover, GABAergic neurotransmission is affected, contributing to behavioral dysfunctions during AD. Considering the multi-factorial character of AD, we have designed and synthesized molecules, which combine more than one pharmacophores. Such compounds could be able to act at various targets associated with AD and thus achieving more effective treatment of the disease. We have used carboxylic acids with antioxidant activity (butylated hydroxy-benzoic acid, butylated hydroxy-cinnamic acid, ferulic acid, sinapic acid, trolox) which were amidated with moieties that could act in the CNS. Furthermore, we have used carboxylic acids without antioxidant characteristics in order to compare other actions of the compounds with the respective actions of compounds with simultaneous potential. Amines we used for the synthesis were the following: •Proline methyl-ester: proline includes the pharmacophore of nootropic drugs (piracetam, aniracetam) •GABA methyl-ester: GABA is the main inhibitory neurotransmitter in brain •Gabapentin methyl-ester: gabapentin decreases the synaptic function by inhibiting Ca2+ and Na+ channels •Nipecotic acid ethyl-ester: nipecotic acid is a GABA reuptake inhibitorAll compounds were purified by flash column chromatography and identified by spectroscopic techniques (1H-NMR, 13C-NMR). The synthesized compounds were tested for their antioxidant potential through their inhibitory effect on lipid peroxidation and their ability to reduce the stable free radical DPPH. In addition, their activity against protein glycation induced by reducing sugars (fructose) was examined. We also tested their inhibitory activity against AchE and their effect on paw oedema produced by carrageenan in rats. Finally, we tried to estimate the ability of our compounds to penetrate Blood-Brain-Barrier (BBB), as they are supposed to act in the CNS.Compounds with antioxidant moieties and high lipophilicity proved to possess very good antioxidant activity, both as lipid peroxidation inhibitors and as DPPH scavengers. Trolox derivatives proved to be the most active antioxidant compounds with IC50 values lower than 10μΜ. Compounds with antioxidant potential inhibited the formation of AGEs significantly (35-56% at 1mM). Additionally, some of our compounds had moderate to very good inhibitory activity against AchE. Nipecotic acid derivatives were the most promising inhibitors (IC50 values lower than 70μΜ). All compounds inhibited the carrageenan-induced oedema in rats, especially the ones with significant antioxidant activity. Finally, considering ClogP and TPSA values of our molecules, all of them are supposed to reach the CNS adequately. Gabapentin derivatives are expected to be distributed into the brain highly, due to their increased lipophilicity and low TPSA. Our results confirm our successful initial design, since our compounds can act against various targets related to AD and can penetrate the Blood-Brain-Barrier. Therefore, they could be used as lead compounds for further investigation and optimization for the development of multi-functional molecules against Alzheimer’s Disease.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2019
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papagiouvannis, Georgios
- Παπαγιουβάννης, Γεώργιος
Subjects
dc:subject × 12Rights
dc:rights- Statement dc:rights
-
- BY
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/46758